Abstract
The indisputed advantages of the pharmacological cardioversion of recent onset atrial fibrillation (good and at times high efficacy, action rapid and often during drug infusion, very good patient compliance, no need for hospitalization) have stimulated the interest of several authors to test both the efficacy of antiarrhythmic drugs and the possible preferential indications for each of them. In our opinion, there are three main factors that must be taken into consideration in choosing the kind of drug for atrial fibrillation (AF) cardioversion: 1) arrhythmia duration, 2) the clinical context in which it takes place, 3) ventricular function.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Goy JJ, Gbric M, Hurni M, Finci L, Maendly R, Duc J, Sigwart U (1985) Conversion of supraventricular arrhythmias to sinus rhythm using flecainide. Eur Heart J 6: 518 – 524
Borgeat A, Goy JJ, Maendly R, Kaufman U, Grbic M, Sigwart U (1986) Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 58: 496 – 498
Suttorp MJ, Kingma JH, Jessuron ER, Lie-A-Huen L, Van Hemel LM, Lie KI (1990) The value of class 1C antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 16: 1722 – 1727
Donovan KD, Dobb GJ, Coombs LJ, Kok-Yeng Lee, Weekes JN, Murdock CJ, Clarche GM (1992) Efficacy of flecainide for the reversion of acute onset atrial fibrillation. Am J Cardiol 70: 50A – 55A
Baldi N, Lenti V, Marasco G, Russo VA, Montervino C (1992) Propafenone vs flecainide in the acute treatment of atrial fibrillation of recent onset: a randomized study. New Trends Arrhyth 8: 499 – 505
Capucci A, Gubelli S, Carini G, Frabetti L, Magnani B (1987) Cardioversione farmaco-logica con propafenone di fibrillazione atriale di recente insorgenza. G Ital Cardiol 17: 975 – 982
Bianconi L, Boccadamo R, Pappalardo A, Gentili C, Pistoiese M (1989) Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 64: 335 – 338
Bertini G, Conti A, Fradella G, Francardelli L, Giglioli G, Mangialavori G, Margheri M, Moschi G (1990) Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias. J Emerg Med 8: 15 – 20
Bracchetti D, Palmieri M (1992) Sicurezza ed efficacia del propafenone e.v. nella cardioversione della fibrillazione parossistica di recente insorgenza. G Ital Cardiol 23: 186 (abstr)
Gronda M, Occhetta E, Magnani A, Rognoni G, D’Aurelio M, Prandi MD, Rossi P (1982) Cardioversione del flutter e della fibrillazione atriale con amiodarone ad alte dosi. G Ital Cardiol 12: 628 – 634
Faniel R, Shoenfeld Ph (1983) Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. Eur Heart J 4: 180 – 185
Strasberg B, Arditti A, Sclarovsky S, Lewins RF, Buimovici B, Agmon J (1985) Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. Int J Cardiol 7: 47 – 55
Cowan JC, Gardiner P, Reid DS, Newell DJ, Campbell RWF (1986) A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction.J Cardiovasc Pharmacol 8: 252 – 256
Noc M, Stajer D, Horvat M (1990) Intravenous amiodarone versus verapamil for acute cardioversion of paroxysmal atrial fibrillation to sinus rhythm. Am J Cardiol 65: 679 – 680
Capucci A, Lenzi T, Boriani G, Trisolino G, Binetti N, Cavazza M, Fontana G, Magnani B (1992) Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 70: 69 – 72
Donovan KD, Power BM, Hockings BEF, Dobb GJ, Lee K-Y (1995) Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 75: 693 – 697
Villani GQ, Rosi A, Piepoli M, Gandolfmi A, Groppi F, Groppi M, Arruzzoni S, Dieci G, Gazzola U (1990) Efficacia del trattamento orale con flecainide nella fibrillazione atriale parossistica: correlazione con le concentrazioni plasmatiche. G Ital Cardiol 20: 564 – 568
Capucci A, Boriani G, Botto GL, Lenzi T, Rubino I, Falcone C, Trisolino G, Della Casa S, Binetti N, Cavazza M, Sanguinetti M, Magnani B (1994) Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 74: 503 – 505
Capucci A, FACC FESC on behalf of the SATE Group Investigators (1996) Propafenone as acute oral loading therapy in the conversion of recent onset atrial fibrillation is safe and effective. J Am Coll Cardiol 79A (abstr)
Boriani G, Capucci A, Botto GL, Rubino S, Lenzi T, Ongari M, Biffi M, Sabbatani P, Sanguinetti M, Magnani B (1996) Different pharmacologic treatment for converting recent-onset atrial fibrillation: evaluation on 377 patients. J Am Coll Cardiol 80A (abstr)
Crijns HJG, Van Wisk LM, Van Gilst WH, Kingma JH, Van Gelder IC, Lie KI (1988) Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate.Comparison of two regimens. Eur Heart J 9: 634 – 638
Baldi N, Russo VA, Morrone V, Marasco G, Polimeni G, Conserva R, Tripaldi R, Angelini E (1995) Relation between plasma levels and efficacy of flecainide and propafenone, by a single oral loading dose, for treatment of atrial fibrillation of recent onset. New Trends Arrhyth 11: 251 – 256
Botto GL, Bonini W, Broffoni T, Falcone C, Mauri R, Molteni S, Tettamanti MG, Ferrari G (1994) Trattamento della fibrillazione atriale di recente insorgenza in pronto soccorso: confronto randomizzato, controllato con placebo tra il carico orale di propafenone o di digossina. G Ital Cardiol 24: 630 (abstr)
Klein GJ, Bashore TM, Sellers TD, Pritchett ELC, Smith WM, Gallagher JJ (1979) Ventricular fibrillation in the Wolff-Parkinson-White. N Engl J Med 301: 1080 – 1085
Wellens HJ, Durrer D (1973) Effect of digitalis on atrioventricular conduction and circus-movement tachycardias in patients with Wolff-Parkinson-White syndrome. Circulation 47: 1229 – 1233
Harper RW, Whitford E, Middlebrook K, Federman J, Anderson S, Pitt A (1982) Effect of verapamil on the electrophysiologic properties of the accessory pathway in patients with the Wolff-Parkinson-White syndrome. Am J Cardiol 50: 1323 - 1330
Michel B, Goy JJ, Kappenberger L (1989) Syndrome de Wolff-Parkinson-White et verapamil: à propos d’un cas de fibrillation auricolaire. Schweiz Med Wochenschr 13/119(19): 630 – 634
Vitale P, De Stefano R, Auricchio A (1986) Possibile pericolosità dell’amiodarone per via endovenosa rapida nel corso di tachicardia da rientro in soggetti con WolffParkinson-White. G Ital Cardiol 16: 969 – 974
Neuss H, Buss J, Schlepper M, Berthold R, Mitrovic V, Kramer A, Musial WJ (1983) Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome. Eur Heart J 4: 347 – 353
Hellenstrand KJ, Nathan AW, Bexton RS, Camm AJ (1984) Electrophysiologic effects of flecainide acetate on sinus node function anomalous atrioventricular connections and pacemaker threshold. Am J Cardiol 53 (suppl B): 30 – 38
Breithardt G, Borggrefe M, Wiebringhaus E, Seipel L (1984) Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiological findings and long-term follow-up. Am J Cardiol 54: 29D – 39D
Kim SS, Lal R, Ruffy R (1986) Treatment of paroxysmal supraventricular tachycardia with flecainide acetate. Am J Cardiol 58: 80 – 85
Shen EN, Keung E, Huycke E, Dohrmann ML, Nguyenn N, Morady F, Sung RJ (1986) Intravenous propafenone for termination of reentrant supraventricular tachycardia. A placebo-controlled, randomized, double-blind, crossover study. Ann Intern Med 105: 655–659
Hammil SC, Mc Laran CJ, Wood DL, Osborne MJ, Gersh BJ, Holmes DR (1987) Double blind study of intravenous propafenone for paroxysmal supraventricular reentrant tachycardia. J Am Coll Cardiol 9: 1364 – 1368
Ludmer PL, Mc Cowan NE, Antman EM, Friedman PL (1987) Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. J Am Coll Cardiol 9: 1357 – 1363
Dubuc M, Kus T, Campa MA, Lambert C, Rosengarten M, Shenasa M (1989) Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome. Am Heart J 117: 370 – 376
Kappenberger LJ, Fromer MA, Shenasa M, Gloor HO (1985) Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. Clin Cardiol 8: 321 – 326
Manolis AS, Salen DN, Estes NAM (1989) Electrophysiologic effects, efficacy and tolerance of class 1C antiarrhythmic agents in Wolff-Parkinson-White syndrome. Am J Cardiol 63: 746 – 750
Ogunkelu IB, Damato AN, Akthar M, Reddy CP, Caracta AR, Lau SH (1976) Electrophysiologic effects of procainamide in subtherapeutic dose on human atrio-ventricular conduction system. Am J Cardiol 37: 724 – 731
Hellenstrand KJ, Bexton RS, Nathan AW, Spurrel RA, Camm AJ (1982) Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J 48: 140 – 148
Pristowsky EN, Heger JJ, Chilson DA, Miles WM, Hubbard J, Zipes DP (1984) Antiarrhythmic and electrophysiologic effects of oral propafenone. Am J Cardiol 54: 26D – 28D
Benaim R, Uzan C (1978) Les effets antiarrhithmiques de l’amiodarone injectable (à propos de 153 cas). Rev Med 19: 1959 – 1963
Morady F, Scheinman MM, Shen E, Shapiro W, Sung RJ, Di Carlo L (1983) Intravenous amiodarone in the acute treatment of recurrent symptomatic ventricular tachycardia. Am J Cardiol 51: 156 – 159
Horowitz LN, Spielma SR, Grenspan AM, Mintz GS, Morganroth J, Brown R, Brady PM, Kay HR (1985) Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 6: 1402 – 1407
Blevins RD, Kerin NZ, Benaderet D, Frumin H, Faitel K, Jarandilla R, Rubenfire M (1987) Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 147: 1401 – 1404
Brodsky MA, Allen BJ, Walker III CJ, Casey TP, Luckett CR, Henry WL (1987) Amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 60: 572 – 575
Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillige H, Wiesfeld ACP, Lie KI (1992) Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 267: 3289 – 3293
Skoulagiris J, Rothlisberger C, Skudicky D, Essop MR, Wisenbaught T, Sareli P (1993) Effectiveness of amiodarone and electrical cardioversion for chronic rheumathic atrial fibrillation after mitral valve surgery. Am J Cardiol 72: 423 – 427
Pfisterer M, Burkart F, Muller-Brand J, Kiowski W (1985) Important differences between short and long-term hemodynamic effects of amiodarone in patients with chronic ischemic heart disease at rest and during ischemia-induced left ventricular dysfunction. J Am Coll Cardiol 5: 1205 – 1211
Sheldon RS, Mitchell LB, Duff HJ, Wyse DG, Manyar DE, Reynolds K (1988) Right and left ventricular function during chronic amiodarone therapy. Am J Cardiol 62: 736–740
Mostow ND, Vrobel TR, Noon D, Rakita L (1986) Rapid suppression of complex ventricular arrhythmias with high-dose oral amiodarone. Circulation 73: 1231 – 1238
Deedwania PC, Singh BN, Flechter R, Fisher S, Singh S (1996) Amiodarone improves survival by restoring and maintenance sinus rhythm in patients with chronic atrial fibrillation, dilated cardiomyopathy and congestive heart failure. Circulation 94 (suppl I): 667
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Italia
About this chapter
Cite this chapter
Baldi, N., Russo, V.A., Morrone, V., Marasco, G., Polimeni, G. (1998). Atrial Fibrillation: Which Drug to Prefer for Acute Cardioversion?. In: Raviele, A. (eds) Cardiac Arrhythmias 1997. Springer, Milano. https://doi.org/10.1007/978-88-470-2288-1_5
Download citation
DOI: https://doi.org/10.1007/978-88-470-2288-1_5
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2290-4
Online ISBN: 978-88-470-2288-1
eBook Packages: Springer Book Archive